Product Availability Key

  • Mexico and Canada flagMexico and Canada
  •  Outside North America flag Outside North America
  •  US flag US
  • Mexico and Canada flag
  •  Outside North America flag
  •  US flag

CAT #: 40880108

LymphoTrack® T-Cell Low Positive Control

Introduction

Measurable Residual Disease (MRD) testing by Nest-Generation Sequencing (NGS) is a proven tool in the development of management strategies for hematologic malignancies.   The National Comprehensive Cancer Network (NCCN) guidelines now recommend MRD testing for several lymphoid cancers, including multiple myeloma (MM), acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).1,2,3,4   European LeukemiaNet (ELN) guidelines recommend MRD testing following induction and consolidation courses
to assess remission status and determine kinetics of disease response, and sequentially beyond consolidation to detect impending morphologic relapse.5

 

Product Use

The RUO LymphoTrack Low Positive Controls and LymphoQuant® Internal Controls are used in conjunction with LymphoTrack Assays to estimate the rearranged cell equivalents within each sample tested.

Product Details

  • Description

    LymphoTrack Assays, controls and software together provide a comprehensive NGS solution for use in your laboratory to identify and track Ig and TCR gene rearrangements as well as somatic hypermutation status.   The same streamlined LymphoTrack Assay workflow is used for the identification of clonal gene rearrangements as well as MRD assessment (e.g., tracking clonal sequences).   Once specific clonal sequences have been identified, the MRD assessment uses the LymphoTrack Low Positive Control, instead of the positive control included with the LymphoTrack Assay kit, and includes the LymphoQuant Internal Controls, which enable accurate monitoring of hematological disease in longitudinal studies.

    The LymphoQuant T-cell Low Positive Control verifies the run validity and confirms assay sensitivity of the assay, ensuring consistent assay performance.  The LymphoQuant T-cell Internal Control serves as a reference to determine the clonal TRG and TRB cell equivalents present within unknown samples, enabling consistent and objective disease monitoring over time.

  • Overview

    Key Benefits

    • LymphoTrack NGS workflows are streamlined and easy to implement in-house
    • Track clonal sequences in subsequent samples with > 1 x 10-6 sensitivity*
      *the amount of input DNA has a significant and direct impact on assay sensitivity
    • Calculate clonal cell equivalents for accurate MRD assessment over time
    • Detect refractory and relapsed disease earlier in oncology studies
    • Monitor and assess the effectiveness of therapies and/or remission status in oncology studies

References

1. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 2.2020.
2. NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 2.2019.
3. NCCN Clinical Practice Guidelines in Oncology: Pediatric Acute Lymphoblastic Leukemia. Version 1.2020.
4. NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia. Version 1.2020.
5. Dohner et al. Blood. 2017 Jan 26; 129(4): 424–447.

Disclaimer

These products are for Research Use Only.  Not for use in diagnostic procedures.

Legal Notice

Now Available

Our New Document Search Feature
SEARCH ⟶

Need Help Placing an Online Order?

Contact our Customer Service Team
CONTACT CUSTOMER SERVICE ⟶

Now Available

Our New Document Search Feature
SEARCH ⟶

Need Help Placing an Online Order?

Contact our Customer Service Team
CONTACT CUSTOMER SERVICE ⟶